Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Research Notes

Open Access

Socio-demographic and behavioural characteristics associated with HSV-2 sero-prevalence in high risk women in KwaZulu-Natal

BMC Research Notes20158:185

https://doi.org/10.1186/s13104-015-1093-0

Received: 11 June 2014

Accepted: 24 March 2015

Published: 5 May 2015

Abstract

Background

The World Health Organization estimates that 536 million people aged 15–49 are infected with Herpes simplex virus type 2 (HSV-2), the causative agent of genital herpes. The aim of this study was to investigate the role of behavioral and demographic factors that contribute to the high HSV-2 sero-prevalence among women participating in a HIV prevention trial. The Methods for Improving Reproductive Health in Africa (MIRA) study assessed the effectiveness the latex diaphragm and lubricant gel on HIV prevention among women in South Africa and Zimbabwe. At screening an interviewer administered questionnaire on demographics and sexual behaviour was obtained. HSV-2 serum antibodies were detected using HerpeSelect™ ELISA IgG. Statistical analysis was performed using STATA release 12.0. This study was registered with ClinicalTrials.gov,number NCT00121459 on the 28th February 2007.

Findings

Of the 3 472 women screened at the Durban research sites 2 218 (73%) had a prevalent HSV-2 infection and 1431 (41%) of the women were also co-infected with HIV. In the multivariate analyses, older women (adjusted odds ratio) [aOR]: 3.49, 95% CI: (2.71,4.49) for >35 years and aOR: 1.82, 95% CI: 1.49, 2.22 for 25–34 years compared with <25 years, p < 0.001 for both comparisons were more likely to be HSV-2 sero-positive. Low level of education (OR: 1.26 95% CI: 1.03, 1.53), having >1 life-time sexual partners (OR: 2.48, 95% CI: 1.92, 3.20), parity >1 (OR: 1.95 95% CI: 1.92, 3.20) and being HIV positive (OR: 6.31, 95% CI: 5.06, 7.88) were significantly associated with HSV-2 infection.

Conclusion

The high sero-prevalence of HSV-2 in the studied population is of great public health importance since this high risk population could act as a reservoir for future infections particularly HIV transmission.

Keywords

HSV-2Sero-prevalenceMultivariate analysisSocio-demographicSexual behaviour

Findings

While bacterial sexually transmitted infections (STIs) such as Chlamydia and Gonorrhoea are curable, viral STIs such as herpes simplex virus, human papillomavirus, hepatitis B and Human immunodeficiency virus (HIV) are deemed to be persistent and incurable [1,2]. The World Health Organization estimates that 536 million people aged 15–49 are infected with Herpes simplex virus type 2 (HSV-2), the causative agent of genital herpes [3]. Annually approximately 23.6 million people in this age group become newly infected with HSV-2. The prevalence rates of HSV-2 infection are reported to be higher in women when compared to men; with the lowest prevalence rates being 13% among West European men and the highest prevalence rates being 70% among sub-Saharan African women [3]. There are several reports suggesting that HSV-2 is a biological co-factor for HIV acquisition [4-7]. A meta-analysis performed by Freeman [8] showed that the relative risk of HIV acquisition associated with HSV-2 was 3.1 (95% confidence interval (CI): 1.7, 5.6). It is suggested that HSV-2 infection may contribute to >50% new HIV infections among women in Sub-Saharan Africa [9]. In South Africa, the prevalence of HSV-2 infection is reported to be 53% [10].

The aim of this analysis was to investigate the role of behavioural and demographic factors that contribute to the high HSV-2 sero-prevalence among women participating in a HIV prevention trial. The Methods for Improving Reproductive Health in Africa (MIRA) study that was conducted between 2003–2005 assessed the effectiveness the latex diaphragm and lubricant gel on HIV prevention among women in South Africa and Zimbabwe [11]. In Durban, the study was conducted in rural Umkomaas and Bothas Hill, southern and western Durban. The study protocol and informed consents were approved by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal. Participants provided written informed consent prior to study procedures being conducted.

At screening, verbal consent to assess initial eligibility, followed by written informed consent for screening procedures, including diagnostic testing and answering an interviewer administered questionnaire on demographics and sexual behaviour was obtained. The full details of this study are described elsewhere [11]. The presence of HSV-2 antibodies was detected using HerpeSelect™ ELISA IgG (Focus Technologies, Cypress, CA, USA) according to the manufacturer’s recommendations with a cut-off value of 1.1. Two HIV rapid tests were done on whole blood samples from venipuncture by use of Determine HIV-1/2 (Abbott Laboratories, Japan) and Oraquick (OraSure Technologies, USA). Urine specimens were collected for polymerase chain reaction (PCR) testing for Neisseria gonorrhea (NG), Chlamydia trachomatis (CT) and Trichomonas vaginalis (TV) (Roche Pharmaceuticals, USA). Univariate and multivariate analyses were performed using logistic regression for both. Multivariate models considered all variables statistically significant (P < 0.10) in the initial analyses and used a forward stepwise method. Statistical analysis was performed using STATA release 12.0 (College Station, Texas, TX, USA).

Of the 3 472 women screened at the Durban research sites 2 218 (73%) had a prevalent HSV-2 infection (Table 1). According to the univariate analyses, socio-demographic associations such as being older (25 years and older) (Odds Ratio (OR) 2.37, 95% Confidence Interval (CI): 2.00,2.81), belonging to a particular ethnic group based on language spoken i.e. isiZulu (OR: 5.47, 95% CI: 4.01, 7.43) having less than high school education (OR: 1.68, 95% CI: 1.43, 1.98), being single/non-cohabiting (OR: 1.54, 95% CI: 1.25, 1.89), and belonging to a particular religion (Christianity) (OR: 1.72, 95% CI: 1.36, 2.18) were significantly associated with HSV-2 infection. The behavioural and biological factors that were significantly associated with HSV-2 infection were: age of sexual debut (<16 years old) (OR: 1.40, 95% CI: 1.19, 1.63), >4 lifetime sexual partner (OR: 5.43 95% CI: 4.33, 6.82) parity >1 (OR: 2.31, 95% CI: 1.90,2.80), lack of contraceptive use (OR: 1.40, 95% CI: 1.26, 1.68), co-infection with Neisseria gonorrhoeae (OR: 2.28, 95% CI: 1.29, 4.05) presenting with a genital ulcer (OR: 3.16, 95% CI: 1.73, 5.74) and being HIV positive (OR: 7.38, 95% CI: 6.01, 9.10).
Table 1

Socio-demographic, behavioural and biological data associated with Herpes Simplex Virus type −2 (HSV-2) in women that presented for screening

HSV-2 at the screening: 2,218/3,472 (73%)

Univariate analysis

Multivariate analysis

 

Total population n = 3472 (%)

Odds ratio (95% CI)

p-value

Odds ratio (95% CI)

p-value

Age groups

     

   <25

1430 (41%)

1

 

1

 

   25-34

1275 (37%)

2.37 (2.00,2.81)

<0.001

1.82 (1.49,2.22)

<0.001

   35+

767 (22%)

3.18 (2.55,3.95)

<0.001

3.49 (2.71,4.49)

<0.001

Language spoken

     

   English/other

191 (6%)

1

   

   Zulu

3281 (94%)

5.47 (4.01,7.43)

<0.001

-

 

Level of education

     

   At least high school

904 (26%)

1

 

1

 

   Less than high school

2568 (74%)

1.68 (1.43,1.98)

<0.001

1.26 (1.03,1.53)

0.021

Religion

     

   Other

325 (9%

1

   

   Christian

3147 (91%)

1.72 (1.36,2.18)

<0.001

-

 

Age at sexual debut

     

   >16 years

2073 (60%)

1

   

   16 years or younger

1399 (40%)

1.40 (1.19,1.63)

<0.001

-

 

Marital/cohabitation status

     

   Married/cohabitating

528 (15%)

1

   

   Not married/not cohabitating

2944(85%)

1.54 (1.25,1.89)

<0.001

-

 

Number of life time sexual partners

     

   1

854 (25%)

1

 

1

 

   2

978 (28%)

2.53 (2.10,3.10)

<0.001

1.89 (1.52,2.34)

<0.001

   3

731 (21%)

3.84 (3.10,4.82)

<0.001

2.30 (1.78,2.96)

<0.001

   4 +

906 (26%)

5.43 (4.33,6.82)

<0.001

2.48 (1.92,3.20)

<0.001

Condom used (ever)

     

   Yes

2438 (71%)

1

   

   No

1034 (29%)

1.03 (0.88,1.22)

0.689

-

 

Parity

     

   None

512 (15%)

1

 

1

 

   >1

2960 (85%)

2.31 (1.90,2.80)

<0.001

1.95 (1.54,2.48)

<0.001

Contraceptive use (any)

     

   Yes

2692 (78%)

1

   

   No

780 (22%)

1.40 (1.26,1.68)

0.001

-

 

HIV status at the screening

     

   seronegative

2041 (59%)

1

 

1

<0.001

   seropositive

1431 (41%)

7.38 (6.01,9.10)

<0.001

6.31 (5.06,7.88)

 

Trichomonas vaginalis infection at the screening

     

   Negative

3242 (94%)

1

   

   Positive

216 (6%)

1.04 (0.76,1.43)

0.786

-

 

Chlamydia trachomatis infection at the screening

     

   Negative

3149 (91%)

1

   

   Positive

309 (9%)

1.00 (0.77,1.30)

0.999

-

 

Neisseria gonorrhoea infection at the screening

     

   Negative

3375 (97%)

1

   

   Positive

97 (3%)

2.28 (1.29,4.05)

0.005

-

 

Genital signs and symptoms 1

     

   Genital epithelial disruption

 

1

   

   No

3403 (98%)

1

 

-

 

   Yes

69 (2%)

1.48 (0.62,3.52)

0.372

  

Genital signs

     

   No

2986 (86%)

1

 

-

 

   Yes

486 (14%)

0.98 (0.69,1.39)

0.895

  

Genital discharge

 

1

   

   No

2500 (72%)

1

 

-

 

   Yes

972 (28%)

0.94 (0.72,1.22)

0.628

  

Genital ulcer

     

   No

3264 (94%)

1

 

-

 

   Yes

208 (6%)

3.16 (1.73,5.74)

<0.001

  

Bacterial Vaginosis infection

     

   No

3160 (91%)

1

 

-

 

   Yes

312 (9%)

1.32 (0.89,1.96)

0.162

  

*CI: Confidence Interval.

1In vulva, vaginal or cervical.

In the multivariate analyses, older women (25 years and older) were more likely to be HSV-2 sero-positive (OR: 1.82, 95% CI: 1.49, 2.22). Women with a lower level of education were also considered to be more likely to be HSV-2 positive (OR: 1.26 95% CI: 1.03, 1.53). Additionally, having >1 life-time sexual partners (OR: 2.48, 95% 1.92, 3.20) parity >1 (OR: 1.95 95% CI: 1.92, 3.20) and being HIV positive (OR: 6.31, 95% CI 5.06, 7.88) were all significantly associated with HSV-2 infection.

In this study, the prevalence of HSV-2 was estimated at 73% with 41% of the women also co-infected with HIV. Behavioural characteristics such as: a high number of life-time sexual partners [12-15], older age [9,10,16,17], parity >1 [15,17] and a low level of education [17] were contributory factors. Biologically, being HIV positive [9,15,16,18], was associated with the high HSV-2 sero-prevalence seen in the study population. The data reported in this study is consistent with previous studies [9,10,16,17].

Consistent with other studies, older age is associated with HSV-2 infection [9,10,16,17]. The prevalence of HSV-2 infection in women with > 4 life-time sexual partners was 2-fold higher when compared with women with just one sexual partner. This finding is strongly supported by previous studies conducted [12-15]. Parity was also strongly associated with HSV-2 infection. Women with a previous pregnancy had a 2-fold higher prevalence for HSV-2 infection when compared to women that were nulliparous. Currently there is limited published literature that explains the association between parity and HSV-2 infections. Older age and parity are probably surrogate measures of cumulative sexual exposure. However, post-partum susceptibility to HSV-2 will be best explained in a prospective analysis. Our findings show that HSV-2 infections was higher in women with a lower level of education (less than high-school education) as compared to women with high-school education. This is consistent with the findings of Uribe-Salas et al. [17].

In this study we found that women that were already HIV positive had 6-fold greater odds of being co-infected with HSV-2 than women that were HIV sero-negative. HIV has been shown to enhance the genital shedding of HSV-2, despite the absence of clinical lesions [19]. In Durban, the MIRA study was undertaken from a peri-urban clinic in Umkomaas and a less urbanised clinic in Botha’s Hill. The women that visited the clinics were at higher risk for HIV and STIs since they were residing in areas termed “hotspots” with excessively high HIV prevalence rates ranging from 39-56%. Diagnosis of HSV-2 was also more common in the hotspots [20].

In this study, we used a cut-off value of 1.1 which has been previously shown to have reduced sensitivity and specificity in detecting HSV-2 antibodies [21]. Despite this limitation, this study was able to identify factors that have been strongly associated with prevalent HSV-2 infections and the factors identified in this study are consistent with previous published findings.The high sero-prevalence of HSV-2 in the studied population is of great public health importance since this high risk population could contribute to the transmission of future infections particularly HIV. This study provides insight into the factors that contribute to prevalent HSV-2 infection. The identification of risk factors for HSV-2 infection could aid in the development and implementation of personalized prevention messages for this infection.

We acknowledge the following limitations of our study: the population studied here volunteered to participate in an HIV/STI prevention clinical trial and therefore could be assumed to be at being at more risk for HIV/STIs. Sexual behaviour data was collected by self-report and therefore introduces the concept of biasness. The HerpeSelect™ ELISA IgG has been shown to have a reduced sensitivity and specificity in populations of high HIV prevalence which could have affected interpretation of the results [21]. And finally, laboratory tests that identified exactly which pathogens caused the ulcers as well as further characterization of the clinical symptoms that fell in the category genital signs would also have made useful discussion points. And finally, due to the cross-sectional design of this study, temporal relationships could not be established.

Declarations

Acknowledgements

We gratefully acknowledge the contribution of the women who participated in this study. We thank the MIRA team at the University of California (San Francisco), Ibis Reproductive Health and members of the HIV Prevention Research Unit (MRC South Africa). We acknowledge the financial support of the Bill and Melinda Gates Foundation (Grant number 21082).

Authors’ Affiliations

(1)
HIV Prevention Research Unit, Medical Research Council
(2)
Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine
(3)
The Kirby Institute, University of New South Wales

References

  1. Ericsson CD, Steffen R, Matteelli A, Carosi G. Sexually transmitted diseases in travelers. Clin Infect Dis. 2001;32(7):1063–7.View ArticleGoogle Scholar
  2. Kaushic C, Roth KL, Anipindi V, Xiu F. Increased prevalence of sexually transmitted viral infections in women: the role of female sex hormones in regulating susceptibility and immune responses. J Reprod Immunol. 2011;88(2):204–9.View ArticlePubMedGoogle Scholar
  3. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ. 2008;86(10):805-12A.View ArticleGoogle Scholar
  4. Ramjee G. Prevalence of HIV among truck drivers visiting sex workers in KwaZulu-Natal, South Africa. Sex Transm Dis. 2002;29(1):44.View ArticlePubMedGoogle Scholar
  5. Ramjee G, Williams B, Gouws E, Van Dyck E, Deken BD, Karim SA. The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. J Acquir Immune Defic Syndr. 2005;39(3):333–9.View ArticlePubMedGoogle Scholar
  6. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362(5):427–39.View ArticlePubMed CentralPubMedGoogle Scholar
  7. Mugo N, Dadabhai SS, Bunnell R, Williamson J, Bennett E, Baya I, et al. Prevalence of herpes simplex virus type 2 infection, human immunodeficiency virus/herpes simplex virus type 2 coinfection, and associated risk factors in a national, population-based survey in Kenya. Sex Transm Dis. 2011;38(11):1059–66. doi: 10.97/OLQ.0b013e31822e60b6.View ArticlePubMedGoogle Scholar
  8. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20(1):73.View ArticlePubMedGoogle Scholar
  9. Kirakoya-Samadoulougou F, Nagot N, Defer M-C, Yaro S, Fao P, Ilboudo F, et al. Epidemiology of herpes simplex virus type 2 infection in rural and urban Burkina Faso. Sex Transm Dis. 2011;38(2):117–23. doi:10.1097/OLQ.0b013e3181f0bef7.View ArticlePubMedGoogle Scholar
  10. Kenyon C, Colebunders R, Buve A, Hens N. P3. 065 Partner-concurrency associated with HSV-2 infection in young South Africans. Sex Transm Infect. 2013;89 Suppl 1:A168-A.View ArticleGoogle Scholar
  11. Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, Blanchard K, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet. 2007;370(9583):251–61.View ArticlePubMed CentralPubMedGoogle Scholar
  12. Cherpes TL, Meyn LA, Krohn MA, Hillier SL. Risk Factors for infection with herpes simplex virus type 2: role of smoking, douching, uncircumcised males, and vaginal flora. Sex Transm Dis. 2003;30(5):405–10.View ArticlePubMedGoogle Scholar
  13. Wald A. Herpes simplex virus type 2 transmission: risk factors and virus shedding. Herpes. 2004;11:130A–7.PubMedGoogle Scholar
  14. Asgari S, Chamani-Tabriz L, Asadi S, Fatemi F, Zeraati H, Akhondi M, et al. HSV-2 seroepidemiology and risk factors among Iranian women: a time to new thinking. Iran Red Crescent Med J. 2011;13(11):818.PubMed CentralPubMedGoogle Scholar
  15. Kapiga SH, Ewings FM, Ao T, Chilongani J, Mongi A, Baisley K, et al. The epidemiology of HIV and HSV-2 infections among women participating in microbicide and vaccine feasibility studies in Northern Tanzania. PLoS One. 2013;8(7):e68825.View ArticlePubMed CentralPubMedGoogle Scholar
  16. Patel P, Bush T, Mayer KH, Desai S, Henry K, Overton ET, et al. Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the United States. Sex Transm Dis. 2012;39(2):154–60.View ArticlePubMedGoogle Scholar
  17. Uribe-Salas F, Conde-Glez C, Juarez-Figueroa L, Hernandez-Castellanos A. Socio-demographic characteristics and sex practices related to herpes simplex virus type 2 infection in Mexican and Central American female sex workers. Epidemiol Infect. 2003;131(2):859.View ArticlePubMed CentralPubMedGoogle Scholar
  18. Van Wagoner NJ, Brown E, Whitley R, Hook III EW. Predictors of undiagnosed herpes simplex virus type 2 seropositivity among persons attending an HIV care clinic. Sex Transm Dis. 2012;39(11):857–9.View ArticlePubMed CentralPubMedGoogle Scholar
  19. Weiss H, Buve A, Robinson N, Van Dyck E, Kahindo M, Anagonou S, et al. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. AIDS. 2001;15:S97–108.View ArticlePubMedGoogle Scholar
  20. Wand H, Ramjee G. Targeting the hotspots: investigating spatial and demographic variations in HIV infection in small communities in South Africa. J Int AIDS Soc. 2010;13(1):1–9.View ArticleGoogle Scholar
  21. Delany-Moretlwe S, Jentsch U, Weiss H, Moyes J, Ashley-Morrow R, Stevens W et al. Comparison of Focus HerpesSelect® and KalonTM HSV-2 gG2 ELISA serological assays to detect herpes simplex virus type 2 (HSV-2) antibodies in a South African population. Sex Transm Infect. 2009. doi:10.1136/sti.2009.036541.Google Scholar

Copyright

© Abbai et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement